Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 5/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | LPL | P06858 | 3/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009019 | 0.83 | THRB (0.34) | ENPP2 | |
| SCHEMBL12831165 | 0.82 | MAPT (0.40) | NOS1NOS2KDM4EMAPTNOS3 | |
| SCHEMBL1303307 | 0.79 | LPL (0.48) | ENPP2MAPTLPLLIPG | |
| SCHEMBL23732879 | 0.78 | KMT2A (0.41) | DYRK1AENPP2KDM4E | |
| SCHEMBL15940842 | 0.76 | ENPP2 (0.50) | DYRK1AENPP2KDM4ELPLLIPG | |
| SCHEMBL21278561 | 0.75 | CYP2A6 (0.41) | DYRK1APRMT6EPHX2NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL29955592 | 0.75 | ENPP2 (0.48) | ENPP2LPLLIPG | |
| SCHEMBL2067301 | 0.74 | CYP11B2 (0.42) | ENPP2LPLLIPG | |
| SCHEMBL21994422 | 0.74 | ENPP2 (0.56) | ENPP2KDM4E | |
| SCHEMBL17847176 | 0.74 | GABRA1 (0.34) | ENPP2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-9624246-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20160229871-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229871-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | DYRK1A 1726/4885PRMT6 731/4885EPHX2 3762/4885 |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | DYRK1A 1726/4885PRMT6 731/4885EPHX2 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.